JANG,HAGOON
Senior Research Scientist - Basic Life, Pediatrics - Human Gene Therapy
All Publications
-
NEAT1 remodeling rewires the MYC degradation pathway.
Nucleic acids research
2026; 54 (19)
Abstract
MYC is among the most frequently amplified oncogenes in human cancer, yet its intrinsically disordered nature has rendered it refractory to direct pharmacological targeting. Here, we demonstrate that the long noncoding RNA NEAT1_1 functions as a molecular gatekeeper that controls MYC protein stability by regulating its access to the E3 ubiquitin ligase UBR5. We show that NEAT1_1 forms a ribonucleoprotein (RNP) complex with both MYC and UBR5, and that NEAT1_1 suppression disrupts this interaction, leading to decreased MYC polyubiquitination and enhanced protein stability. To systematically map the regulatory architecture of NEAT1_1 without altering its abundance, we screened 88 antisense oligonucleotide (ASO) mixmers tiling across the transcript. Strikingly, this phenotypic screen identified region-specific mixmers that elicit bidirectional control over MYC, either driving robust MYC destabilization or promoting its stabilization in a strictly expression-independent manner. Mechanistically, MYC-destabilizing mixmers selectively enhance the interaction between MYC and UBR5 to accelerate proteasomal degradation. A focused CRISPR screen targeting the ubiquitin-proteasome pathway independently validated UBR5 as the essential E3 ligase mediating this mixmer-induced turnover. In vivo, our lead mixmer ASO_#24 significantly suppressed tumor growth in MYC-high xenografts, whereas MYC-low tumors remained unaffected. Our findings reveal that the functional output of a scaffold lncRNA is encoded in its sub-domain architecture rather than bulk transcript levels, establishing domain-specific RNA targeting as a tractable strategy to rewire protein turnover pathways for otherwise undruggable oncogenes.
View details for DOI 10.1093/nar/gkag1015
View details for PubMedID 42924439
View details for PubMedCentralID PMC13691374
-
Potential effects of endogenous RNA/DNA hybrids on CRISPR-Cas9-mediated homology-directed repair
MOLECULAR THERAPY NUCLEIC ACIDS
2026; 37 (2)
View details for DOI 10.1016/j.omtn.2026.102880
View details for Web of Science ID 001722913600001
-
Potential effects of endogenous RNA/DNA hybrids on CRISPR-Cas9-mediated homology-directed repair.
Molecular therapy. Nucleic acids
2026; 37 (2): 102880
Abstract
Recombinant adeno-associated virus (rAAV) vectors and CRISPR-Cas9 are widely used in gene therapy. However, how endogenous DNA secondary structures may potentially affect genome editing outcomes is not fully understood. RNA/DNA hybrids (R-loops), which form mostly during transcription, are dynamically regulated in cells and have been implicated in influencing DNA repair pathway choice. Here, we investigated whether genomic R-loops are associated with differences in Cas9-mediated genome editing outcomes in vitro and in vivo. By targeting regions with relatively low or high R-loop levels within the murine albumin (Alb) and actin (Actb) loci, we observed comparable insertion/deletion (indel) frequencies across sites with different R-loop abundance. In contrast, homology-directed repair (HDR) efficiency appeared reduced at R-loop-enriched sites in proliferating hepatocyte-derived cells (HEPA1-6) but not in quiescent hepatocytes in vivo. Manipulations resulting in reducing R-loop levels, including RNaseH1 overexpression or pharmacological induction of G1 arrest were associated with increased HDR at these genomic sites. In addition, T cell activation correlated with elevated R-loop accumulation suggesting they might influence ex vivo genome editing. Together, these observations suggest that endogenous R-loop levels might influence HDR efficiency during Cas9-mediated editing and is a parameter to consider when designing genome editing strategies.
View details for DOI 10.1016/j.omtn.2026.102880
View details for PubMedID 41909468
View details for PubMedCentralID PMC13022658
-
lnc122 RNA prevents liver tumorigenesis in MYC-driven liver cancer.
JHEP reports : innovation in hepatology
2026: 101916
Abstract
Extensive research has shown that the microRNA-122 (miR-122) plays an important role in liver homeostasis, and its dysregulation has been implicated in various liver pathologies such as liver cancer and non-alcoholic fatty liver disease. The primary transcript for miR-122, long non-coding RNA 122 (lnc122) has traditionally only been considered an intermediate product for mature miR-122.We used CRISPRi to inhibit lnc122 RNA expression in hepatoma cells and mouse livers with and without expression of mature miR-122 RNA to determine if a lnc122 RNA has a separate function. These models were used in combination of RNAseq, Gene Set Enrichment Analysis, RNA pulldown-mass spectrometry, and a CRSIRPi/CRISPRa mediated liver tumor model to establish the specific role of lnc122 in hepatic homeostasis.We demonstrate that lnc122 RNA has a distinct tumor suppressive role that is separate from the anti-proliferative function of miR-122. Specifically, lnc122 RNA promotes MYC protein degradation by stabilizing the MYC-UBR5 E3 ubiquitin ligase protein complex. Unlike other E3 ubiquitin ligases for MYC, UBR5 is co-amplified with MYC in >40% of human cancers due to their close location on the human genome and lnc122 is indispensable for efficient MYC degradation by UBR5. Paired patient liver and tumor samples showed decreased concentrations of lnc122 RNA in tumors. Furthermore, reducing the lnc122 RNA transcripts in mouse liver exacerbated MYC-driven liver tumorigenesis. Although lnc122 expression is restricted to the liver, exogenous expression of lnc122 in non-hepatic transformed cells also destabilized MYC protein.Our findings indicate that lnc122 RNA has a synergistic role with miR-122 in the surveillance and prevention of liver tumorigenesis and may represent a new target for treating MYC-driven human cancers.The study demonstrates that lnc122 RNA not only is a precursor for miR-122 but functions in forming a ubiquitination complex via UBR5, and responsible for limiting the half-life of MYC protein. Loss of lnc122 RNA expression promotes liver cancer perhaps categorizing it as tumor-suppressor gene. Further studies to develop agents to enhance the activity of this complex may offer a new therapeutic approach to treat hepatocellular carcinoma.
View details for DOI 10.1016/j.jhepr.2026.101916
View details for PubMedID 42250762
-
NEAT1 lncRNA Structure-Mediated Functional Modulation as a Novel Therapeutic Approach for MYC-Driven Cancers.
CELL PRESS. 2025
View details for Web of Science ID 001493880500164
-
<i>Tales from the R-loops</i>: how RNA/DNA hybrids may influence CRISPR/Cas9-mediated homologous recombination gene editing outcomes
CELL PRESS. 2025
View details for Web of Science ID 001587763700137
-
Screening for Cellular Factors Underlying Mechanisms of AAV Tropism
CELL PRESS. 2024: 37-38
View details for Web of Science ID 001332783400070
-
Promoterless AAV Gene Targeting Vectors Favor Integration into the Albumin Locus Regardless of Homology Arm Sequences
CELL PRESS. 2023: 738-739
View details for Web of Science ID 001045144203313
-
Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice.
Nature biotechnology
2022
Abstract
Homologous recombination (HR)-based gene therapy using adeno-associated viruses (AAV-HR) without nucleases has several advantages over classic gene therapy, especially the potential for permanent transgene expression. However, the low efficiency of AAV-HR remains a major limitation. Here, we tested a series of small-molecule compounds and found that ribonucleotide reductase (RNR) inhibitors substantially enhance AAV-HR efficiency in mouse and human liver cell lines approximately threefold. Short-term administration of the RNR inhibitor fludarabine increased the in vivo efficiency of both non-nuclease- and CRISPR/Cas9-mediated AAV-HR two- to sevenfold in the murine liver, without causing overt toxicity. Fludarabine administration induced transient DNA damage signaling in both proliferating and quiescent hepatocytes. Notably, the majority of AAV-HR events occurred in non-proliferating hepatocytes in both fludarabine-treated and control mice, suggesting that the induction of transient DNA repair signaling in non-dividing hepatocytes was responsible for enhancing AAV-HR efficiency in mice. These results suggest that use of a clinically approved RNR inhibitor can potentiate AAV-HR-based genome-editing therapeutics.
View details for DOI 10.1038/s41587-022-01240-2
View details for PubMedID 35393561
-
Lnc122-The miR122 Precursor Has an Independent Role as a Tumor Suppressor in Liver
CELL PRESS. 2022: 514
View details for Web of Science ID 000794043702274
-
Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex.
Molecular therapy : the journal of the American Society of Gene Therapy
2021; 29 (3): 1016–27
Abstract
Recombinant adeno-associated virus (rAAV) vectors have the unique property of being able to perform genomic targeted integration (TI) without inducing a double-strand break (DSB). In order to improve our understanding of the mechanism behind TI mediated by AAV and improve its efficiency, we performed an unbiased genetic screen in human cells using a promoterless AAV-homologous recombination (AAV-HR) vector system. We identified that the inhibition of the Fanconi anemia complementation group M (FANCM) protein enhanced AAV-HR-mediated TI efficiencies in different cultured human cells by ∼6- to 9-fold. The combined knockdown of the FANCM and two proteins also associated with the FANCM complex, RecQ-mediated genome instability 1 (RMI1) and Bloom DNA helicase (BLM) from the BLM-topoisomerase IIIα (TOP3A)-RMI (BTR) dissolvase complex (RMI1, having also been identified in our screen), led to the enhancement of AAV-HR-mediated TI up to ∼17 times. AAV-HR-mediated TI in the presence of a nuclease (CRISPR-Cas9) was also increased by ∼1.5- to 2-fold in FANCM and RMI1 knockout cells, respectively. Furthermore, knockdown of FANCM in human CD34+ hematopoietic stem and progenitor cells (HSPCs) increased AAV-HR-mediated TI by ∼3.5-fold. This study expands our knowledge on the mechanisms related to AAV-mediated TI, and it highlights new pathways that might be manipulated for future improvements in AAV-HR-mediated TI.
View details for DOI 10.1016/j.ymthe.2020.10.020
View details for PubMedID 33678249
-
A Leu(CAG)-tRNA derived small RNA regulates ribosomal protein S28 after translation initiation in both human and mouse liver cancers
AMER ASSOC CANCER RESEARCH. 2020
View details for DOI 10.1158/1538-7445.AM2020-LB-343
View details for Web of Science ID 000590059302367
-
Proteins Complex of the Fanconi Anemia Pathway as Determinant of AAV-Mediated Genomic Targeted Integration
CELL PRESS. 2020: 459
View details for Web of Science ID 000530089302154
-
A tRNA-Derived Small RNA Regulates Ribosomal Protein S28 Protein Levels after Translation Initiation in Humans and Mice.
Cell reports
2019; 29 (12): 3816
Abstract
tRNA-derived small RNAs (tsRNAs) have been implicated in many cellular processes, yet the detailed mechanisms are not well defined. We previously found that the 3' end of Leu-CAG tRNA-derived small RNA (LeuCAG3'tsRNA) regulates ribosome biogenesis in humans by maintaining ribosomal protein S28 (RPS28) levels. The tsRNA binds to coding (CDS) and non-coding 3' UTR sequence in the RPS28 mRNA, altering its secondary structure and enhancing its translation. Here we report that the functional 3' UTR target site is present in primates while the CDS target site is present in many vertebrates. We establish that this tsRNA also regulates mouse Rps28 translation by interacting with the CDS target site. We further establish that the change in mRNA translation occurred at a post-initiation step in both species. Overall, our results suggest that LeuCAG3'tsRNA might maintain ribosome biogenesis through a conserved gene regulatory mechanism in vertebrates.
View details for DOI 10.1016/j.celrep.2019.11.062
View details for PubMedID 31851915
-
Amino-Acylated LeuCAG3 ' tsRNA Mediates Translational Elongation of Ribosomal Protein S28 mRNA and is a Key Regulatory Step in Ribosome Biogenesis
CELL PRESS. 2019: 302
View details for Web of Science ID 000464381003102